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Elevated white cell count at commencement of peritoneal dial-
ysis predicts overall and cardiac mortality.
Background. Higher total white blood cell counts (WCC)
have been shown in the general population to be strongly and in-
dependently predictive of coronary heart disease and all-cause
mortality. The aim of the present study was to evaluate the prog-
nostic value of WCC in patients commencing peritoneal dialysis
(PD).
Methods. A cohort of 323 patients (mean age 55.1 ±
17.7 years, 54% male, 81% Caucasian) commencing PD at
the Princess Alexandra Hospital between January 1, 1998 and
March 31, 2003 were prospectively followed until death, com-
pletion of PD therapy, or otherwise to the end of the study
(January 2, 2004), at which point data were censored. Individu-
als with failed renal transplants (N = 17) and those with acute
infections at the time of PD onset (N = 12) were not included.
A multivariate Cox’s proportional hazards model was applied
to calculate hazard ratios and adjusted survival curves for time
to death or cardiac death, adjusting for baseline demographic,
clinical, and laboratory characteristics.
Results. Median actuarial patient survival was 3.9 years [95%
confidence interval (CI) 3.2–4.7 years]. The highest quartile of
WCC (>9.4×109/L) was significantly and independently associ-
ated with increased risks of both death from all causes [adjusted
hazard ratio (HR) 2.27, 95% CI 1.09–4.74, P < 0.05] and car-
diac death (HR 3.75, 95% CI 1.2–11.8, P < 0.05). Other adverse
risk factors included older age, lower serum albumin, and the
presence of coronary artery disease. Similar associations were
found between mortality and PMN count, but not lymphocyte
count.
Conclusion. Elevated baseline WCC or PMN count at the
commencement of PD (in the absence of acute infection)
strongly predicts all-cause and cardiovascular mortality. These
data suggest that new PD patients with higher WCC may war-
rant closer monitoring and extra attention to modifiable cardio-
vascular risk factors.
Elevated total white blood cell counts (WCC) have
been shown in the general population to be strongly and
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independently predictive of coronary heart disease and
all-cause mortality [1–9]. The mechanisms underlying this
relationship are not certain, but may involve the presence
of subclinical atherosclerosis, direct leukocyte-induced
endothelial injury, or indirect associations with other car-
diovascular risk factors (including smoking, malnutrition,
and inflammation) [10–12].
WCCs have also been found to be significantly elevated
in hemodialysis populations [13], where the prevalence of
cardiovascular disease is increased approximately 20- to
100-fold compared with the general population [14]. Two
retrospective observational cohort studies of hemodial-
ysis patients have shown that increased polymorphonu-
clear leukocyte (PMN) counts and reduced lymphocyte
counts correlate with nutritional and inflammatory in-
dices, but are nevertheless independently predictive of
total mortality [13, 15].
To date, there have been no published studies of the
prognostic value of WCC, PMN count, or lymphocyte
count in peritoneal dialysis (PD) patients. However, it
is conceivable that the predictive value of these param-
eters in this setting may be quite different from that of
hemodialysis populations due to the fact that hemodialy-
sis may itself be associated with an acute-phase response
[16–18] due to prosthetic vascular access, bioincompati-
ble membranes, acetate dialysate buffer, bacterial frag-
ments in the dialysate, and endotoxins originating from
the dialysis water supply. In contrast, inflammatory mark-
ers such as C-reactive protein (CRP) have been reported
to fall with time on PD and to be significantly lower in
PD patients compared with hemodialysis patients [16].
The aim of the present study was to determine the value
of a single baseline WCC, PMN count, and lymphocyte
count in predicting cardiovascular and all-cause mortal-
ity in a prospective, observational cohort of incident PD
patients.
METHODS
Study population
All patients commencing PD at the Princess Alexandra
Hospital between January 1, 1998 and March 31, 2003 who
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were not previously treated with renal transplantation or
immunosuppressive agents, and who did not have acute
infections at the time of commencement of PD, were in-
cluded in the study. They were treated with continuous
ambulatory PD (CAPD) or automated PD (APD) us-
ing conventional dialysate (Dianeal PD4, 1.5% or 2.5%
glucose; Baxter Healthcare, Sydney, Australia). CAPD
patients were prescribed either 2 or 2.5 L exchanges 2, 3,
or 4 times daily, depending on body size and level of resid-
ual renal function. APD patients were exchanged with 8
to 12 L overnight, usually with 1 or 2 daytime exchanges.
Dialysate glucose concentration varied depending on the
individual patient’s requirement for ultrafiltration. For
those individuals who ultrafiltrated less than 1 L per
day despite optimization of dwell time, curtailment of
fluid intake, and the institution of a diuretic, icodextrin
(Extraneal 7.5%; Baxter Healthcare, Castlebar, Ireland)
was administered as an 8- to 10-hour dwell either dur-
ing the day for APD patients or overnight for CAPD
patients. Bicarbonate/lactate-buffered dialysate (Phys-
ioneal; Baxter Healthcare) was substituted for conven-
tional dialysate in the small proportion of patients who
experienced inflow pain. All patients were prescribed di-
etary protein and energy intakes of 1.3 g and 35 kcals
per kg of body weight, respectively. Dialysis prescription
was modified to achieve a minimum total weekly Kt/V of
at least 1.7, and a normalized total creatinine clearance
(CCR) of at least 50 L/week/1.73m2.
At baseline, clinical and biochemical data were
recorded, including demographic characteristics, body
mass index (BMI), cause of end-stage renal failure,
smoking history, presence of diabetes mellitus, coronary
artery disease (previous myocardial infarction, angina
pectoris, or coronary revascularization procedure), cere-
brovascular disease (previous stroke, transient ischemic
attack, or carotid revascularization procedure), and pe-
ripheral vascular disease (previous intermittent claudi-
cation, ischemic leg ulcer, peripheral revascularization,
or amputation for critical limb ischemia). Nonfasting,
early morning, venous blood samples were collected on
the day of dialysis commencement for determining total
and differential WCC (Coulter counter) and serum con-
centrations of urea, creatinine, albumin, and CRP (high-
sensitivity Beckman Coulter IMMAGE nephelometry;
Fullerton, CA, USA). Glomerular filtration rate (GFR)
immediately prior to PD onset was calculated by the
Cockcroft-Gault formula [19] and corrected for body sur-
face area [20].
All patients were followed until death, completion of
PD therapy, or otherwise to the end of the study (Febru-
ary 1, 2004), at which point data were censored. The
causes of patients’ deaths were classified according to
the Australian and New Zealand Dialysis and Transplant
(ANZDATA) Registry codes [21]. If a patient died within
2 months of hemodialysis transfer, they were not censored
because their early mortality was considered to reflect
their health status during the period of failing PD ther-
apy. The primary outcome measures were cardiac and
overall survival.
Statistical analysis
Normality of data was evaluated by the Kolmogorov-
Smirnov test with Lilliefor’s correction. Log transfor-
mations were performed where necessary. Results were
expressed as mean ± SD for continuous parametric data,
median (interquartile range) for continuous nonpara-
metric data, and as frequencies (percentages) for cate-
gorical data. The chi-square test was used to compare
differences between proportions. Population WCCs were
divided into quartiles and analyzed as a categorical vari-
able. A Cox proportional hazards model was applied to
calculate hazard ratios and adjusted survival curves for
time to death or cardiac death, adjusting for age, gen-
der, racial origin, BMI, smoking status, diabetes mellitus,
coronary artery disease, cerebrovascular disease, periph-
eral vascular disease, and baseline laboratory parameters
(albumin, calculated GFR, CRP, and WCC). A backward
stepwise elimination procedure based on the likelihood
ratio was then carried out to remove superfluous vari-
ables from the model until the most parsimonious model
was identified. Adjusted survival curves were estimated
using the Cox average covariate method, which calculates
predicted survival probabilities at the mean levels of the
covariates. Data were analyzed using the software pack-
age SPSS for Windows, release 11.0.0 (SPSS, Inc, North
Sydney, Australia). P values less than 0.05 were consid-
ered significant.
RESULTS
Patient characteristics
A total of 352 incident patients commenced PD dur-
ing the study period. Twenty-nine (8%) patients were ex-
cluded because of previous renal transplantation (N =
17) or acute infection at the time of PD commencement
(N = 12), leaving 323 evaluable patients for analysis. The
baseline characteristics of the study population are de-
picted in Table 1, and are similar to those reported for
Australian and New Zealand PD patient populations by
the ANZDATA Registry [21]. The median (interquartile
range) WCC was 7.4 (5.9–9.4) × 109/L. Corresponding
values for PMN and lymphocyte counts were 5.0 (3.8–6.5)
× 109/L and 1.3 (1.0–1.8) × 109/L, respectively. Follow-up
was complete for all patients.
Overall survival
Overall, 71 (22%) patients died during the course of
the study. Median actuarial survival was 3.9 years (95%
CI 3.3–4.6 years). The causes of death included cardio-
vascular disease (28 or 39%), cerebrovascular accident
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Table 1. Baseline characteristics of the study population (N = 323)
Age years 55.1 ± 17.7
Male 175 (54%)
Racial origin
Caucasian 262 (81%)
Asian 27 (8%)
Maori/Pacific Islander 15 (5%)
Aboriginal/Torres Strait Islander 15 (5%)
Indian 4 (1%)
BMI kg/m2 25.3 ± 5.6
Diabetes mellitus 80 (25%)
Coronary artery disease 98 (30%)
Peripheral vascular disease 59 (18%)
Cerebrovascular disease 27 (8%)
Smoking status
Never 163 (50%)
Former 126 (39%)
Current 34 (11%)
Calculated GFR at PD start mL/min/1.73m2 10.2 ± 4.9
WCC × 109/L 7.4 (5.9–9.4)
PMN count × 109/L 5.0 (3.8–6.5)
Lymphocyte count × 109/L 1.0 (1.3–1.8)
Plasma albumin g/L 35.9 ± 5.4
CRP mg/L 4.0 (2.0–18.0)
Results are expressed as mean ± SD, median (interquartile range), or
frequencies (percentages), depending on data type.
(1 or 1%), infection (10 or 14%), malignancy (5 or 7%),
voluntary withdrawal from therapy (18 or 25%), bowel
infarction (1 or 1%), gastrointestinal hemorrhage (1 or
1%), and unknown (7 or 10%).
Crude mortality rates were significantly increased in
the highest WCC quartile (WCC >9.4 × 109/L) com-
pared with the other quartiles (rates for highest, third,
second, and lowest WCC quartiles were 26.3, 16.6, 9.0,
and 16.0 deaths per 100 patient-years, respectively, P <
0.05). When WCC quartiles were analyzed by univariate
Cox regression analysis, the highest quartile was asso-
ciated with a significantly increased risk of death [haz-
ard ratio (HR) 3.35, 95% CI 1.63–6.87, P = 0.001], while
the lower WCC categories were not significantly differ-
ent from the reference (third) quartile. The other signifi-
cant predictors of death on univariate analysis were lower
serum albumin (HR 0.89, 95% CI 0.86–0.93, P < 0.001),
higher CRP (HR 1.69, 1.20–2.37, P = 0.002), and increas-
ing age (HR 1.58, 95% CI 1.29–1.93, P < 0.001). Mul-
tivariate Cox regression analysis revealed that the sig-
nificant independent predictors of poorer survival were
the highest WCC quartile (HR 2.27, 95% CI 1.09–4.74,
P < 0.05), lower serum albumin, increasing age, and the
presence of coronary artery disease (Table 2). When data
were reanalyzed by combining the lowest 3 quartiles into
a single group, a WCC above the 75th percentile inde-
pendently predicted an increased risk of death (HR 2.21,
95% CI 1.32–3.72, P = 0.003). Similar results were ob-
served when PMN counts were substituted for WCC in
the multivariate Cox model (Fig. 1). However, no sig-
nificant, independent association was observed between
lymphocyte counts and mortality.
Table 2. Predictors of all-cause mortality in 323 incident PD patients
(final Cox proportional hazards model)
Parameter HR CI P value
Age (per 10 years) 1.64 1.33–2.02 <0.001
Coronary artery disease 1.89 1.13–3.16 0.016
Serum albumin (per g/L) 0.89 0.85–0.93 <0.001
WCC quartiles
<5.9 × 109/L 1.45 0.67–3.15 0.35
5.9–7.4 × 109/L 0.92 0.42–2.02 0.84
7.5–9.4 × 109/L 1 Reference
>9.4 × 109/L 2.27 1.09–4.74 0.02
Gender, racial origin, diabetes mellitus, BMI, CRP, calculated GFR,
peripheral vascular disease, and cerebrovascular disease were removed by
backward stepwise elimination.
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Fig. 1. Cox-adjusted overall survival curves for PD patients according
to quartiles of PMN counts (group 1, <3.8 × 109L; group 2, 3.8–5.0 ×
109L; group 3, 5.1–6.5 × 109L; group 4, >6.5 × 109L). The respective
adjusted hazard ratios for quartile groups 1, 2, 3, and 4 were 0.85 (95%
CI 0.41–1.76, P = 0.66), 0.76 (95% CI 0.36–1.61, P = 0.47), 1 (reference),
and 1.96 (95% CI 1.03–3.72, P = 0.04). Other variables adjusted for in
the final multivariate model were age, serum albumin, and coronary
artery disease.
Cardiac survival
Mean actuarial cardiac survival was 4.6 years (95% CI
4.3–4.9). Crude cardiac mortality rates were significantly
increased in the highest WCC quartile (WCC >9.4 ×
109/L) compared with the other quartiles (rates for high-
est, third, second, and lowest WCC quartiles were 14.1,
3.2, 3.3, and 5.7 cardiac deaths per 100 patient-years, re-
spectively, P < 0.05). On univariate Cox regression anal-
ysis, increased cardiac mortality was significantly associ-
ated with the highest WCC quartile (WCC >9.4 × 109/L;
HR 4.21, 95% CI 1.38–12.8, P = 0.01) compared with the
other groups (WCC <5.9 × 109/L HR 1.74, 95% CI 0.49–
6.16; WCC 5.9–7.4 × 109/L HR 0.96, 95% CI 0.24–3.84,
WCC 7.4–9.4 × 109/L reference). The other predictor of
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Table 3. Predictors of cardiac mortality in 323 incident PD patients
(final Cox proportional hazards model)
Parameter HR CI P value
Age (per 10 years) 1.31 1.01–1.72 0.048
Coronary artery disease 2.42 1.02–5.74 0.045
Serum albumin (per g/L) 0.91 0.85–0.98 <0.01
WCC quartiles
<5.9 × 109/L 1.54 0.43–5.51 0.35
5.9–7.4 × 109/L 0.76 0.19–3.10 0.84
7.5–9.4 × 109/L 1 Reference
>9.4 × 109/L 3.75 1.20–11.8 0.02
Gender, racial origin, diabetes mellitus, BMI, CRP, calculated GFR,
peripheral vascular disease, and cerebrovascular disease were removed by
backward stepwise elimination.
cardiac death was lower serum albumin (HR 0.91, 95%
CI 0.85–0.98, P < 0.01), although trends toward increased
cardiovascular mortality were observed with older age
(HR 1.25, 95% CI 0.97–1.62, P = 0.09) and the presence
of diabetes mellitus (HR 2.03, 95% CI 0.96–4.3, P = 0.06).
Using multivariate Cox regression analysis, the signifi-
cant independent predictors of cardiac death were the
highest WCC quartile (WCC >9.4 × 109/L, adjusted HR
3.75, 95% CI 1.20–11.8, P = 0.02), lower serum albumin,
older age, and the presence of coronary artery disease
(Table 3). When data were reanalyzed by combining the
lowest 3 quartiles into a single group, a WCC above the
75th percentile independently predicted an increased risk
of cardiac death (HR 3.93, 95% CI 1.79–8.62, P = 0.001).
Similar findings were observed when PMN counts were
substituted for WCC (Fig. 2), but no association was seen
between lymphocyte counts and cardiac death on multi-
variate analysis.
DISCUSSION
The results of this study demonstrate that an elevated
WCC or PMN count is a significant predictor of all-cause
and cardiac mortality in incident PD patients, indepen-
dent of clinical, biochemical, and inflammatory parame-
ters. The relationship between WCC and death was not
clearly linear, such that only the highest quartile of WCC
(>9.4 × 109/L) was associated with significantly aug-
mented adjusted hazard ratios for overall death (2.27)
and cardiac death (4.21).
These findings are similar to those previously re-
ported in the general and end-stage renal failure pop-
ulations, whereby elevated WCC has been shown to be
strongly and independently predictive of all-cause mor-
tality [1–9, 13, 15]. In a random sample of 7719 North
American hemodialysis patients enrolled in the Dialysis
Outcomes and Practice Patterns Study (DOPPS), Pifer
et al [15] observed that the relative risk of mortality in-
creased with rising quartiles of PMN count. This effect
was independent of the strong inverse correlation identi-
fied between PMN count and serum albumin. Similarly,
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Fig. 2. Cox-adjusted cardiac survival curves for PD patients according
to quartiles of PMN counts (group 1, <3.8 × 109L; group 2, 3.8–5.0 ×
109L; group 3, 5.1–6.5 × 109L; group 4, >6.5 × 109L). The respective
adjusted hazard ratios for quartile groups 1, 2, 3, and 4 were 1.46 (95%
CI 0.44–4.90, P = 0.54), 0.48 (95% CI 0.09–2.49, P = 0.38), 1 (reference),
and 4.03 (1.39–11.6, P = 0.01). Other variables adjusted for in the fi-
nal multivariate model were age, serum albumin, and coronary artery
disease.
Reddan et al [13] found that PMN count (which corre-
lated strongly with total WCC) was a strong independent
predictor of mortality on multivariate Cox proportional
hazards model analysis in a period-prevalent population
of 44,114 patients receiving maintenance hemodialysis at
Fresenius Medical Care facilities in North America. Both
of these studies also observed a significant inverse rela-
tionship between lymphocyte count and mortality, which
was not found in the present study of 323 incident PD pa-
tients. The apparent disparity in findings may be poten-
tially explained by a type 2 statistical error in the current
investigation, given its smaller sample size, or by survivor
bias in the hemodialysis investigations due to the recruit-
ment of prevalent patients. Alternatively, the inclusion of
inflammatory indices (such as CRP) as covariates in the
multivariate models analyzed in our study, but not in the
hemodialysis studies, may have mitigated any observed
association between lymphocyte counts and survival.
A novel finding of our study was the observation that
baseline WCC and PMN counts strongly predicted car-
diac mortality. Such associations have not been previ-
ously reported in end-stage renal failure patients, even
though epidemiologic studies in populations without kid-
ney disease have demonstrated that WCC exerts a simi-
lar [22] or greater [1] risk of coronary heart disease than
total cholesterol levels. Among white blood cell types,
the strongest epidemiologic associations with overall and
cardiac mortality have been with the PMN count [10].
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Moreover, the presence of constitutional neutropenia in
certain ethnic populations, such as Yemenite Jews, ap-
pears to be protective against atherosclerotic complica-
tions [10].
The mechanisms underlying the relationship between
WCC and mortality are uncertain. In epidemiologic stud-
ies, 50% to 65% of the excess risk of higher WCC has
been attributed to smoking [3, 8, 10, 22]. However, the
effects of current or former smoking were adjusted for in
the present study, such that the predictive value of WCC
was independent of this factor. Similarly, it has been sug-
gested that elevated WCC predicts subsequent cardiovas-
cular disease because of the association of both conditions
with inflammation [10, 12]. CRP, a marker of systemic in-
flammation, has been associated with both malnutrition
and cardiovascular outcomes in hemodialysis and PD pa-
tient populations as part of the Malnutrition, Inflamma-
tion and Atherosclerosis (MIA) syndrome [23–30]. In this
study, CRP was a predictor of mortality on univariate
analysis, but its predictive value was not independent of
elevated WCC or PMN count in the multivariate models.
Since WCC is cheaper and easier to measure than CRP,
our results suggest that WCC is preferable to CRP for
predicting PD patient outcomes. Moreover, the adverse
prognostic value of higher WCC (and PMN count) was
independent of a broad range of demographic character-
istics, nutritional indices, biochemical variables, and clin-
ical diagnoses of major comorbidities. Nevertheless, the
possibility that elevated WCC reflected underlying sub-
clinical disease (“reverse causality”), rather than a true
causal relationship, cannot be excluded.
Other authors have speculated that elevated WCC
and PMN counts portend increased risks of subsequent
cardiovascular and all-cause mortality as a result of
leukocyte-induced endothelial injury via altered rheol-
ogy and the release of proteolytic enzymes and oxidants
(such as superoxide radicals and nitric oxide) [10, 31, 32].
Oxygen-free radicals released by activated neutrophils
may also contribute to death through their putative in-
volvement in carcinogenesis and lung disease [10].
Although our study suggests that the adverse prognos-
tic value of a higher WCC for cardiac and all-cause mor-
tality applies equally well to PD patients as it does for
the general population, the investigation does have sev-
eral limitations. These include the relatively small sample
size (323 patients), which may have limited the statisti-
cal power of the WCC differential subanalyses and the
assessment of mortality risk in the lower WCC quartiles.
The investigation was also undertaken at a single center,
which potentially limited its external validity. However,
the characteristics of our population are very similar to
those reported for the Australian and New Zealand PD
patient population [21]. Moreover, the additional vari-
ables found to be predictive of mortality in this investi-
gation (namely serum albumin, age, and the presence of
coronary artery disease) have similarly been identified
as risk factors for death in other PD patient populations
[33–37]. The study was also limited by evaluating baseline
clinical and laboratory parameters only, rather than ex-
amining the effects of longitudinal changes in these vari-
ables on patient outcomes. Nevertheless, this information
is useful for risk stratification at the onset of PD.
CONCLUSION
The results of the present study demonstrated that
higher baseline WCC and PMN counts at the commence-
ment of PD strongly predicted subsequent cardiac and
all-cause mortality. The association between WCC and
mortality is independent of demographic, clinical, nutri-
tional, and inflammatory indices. These data suggest that
new PD patients with higher WCC or PMN counts in the
absence of infection may warrant closer monitoring and
extra attention to modifiable cardiovascular risk factors.
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